Evidence map›Paper›PMID 42601060›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2026

Generation and characterization of a novel MHC-II tetramer for tracking and characterization of toxin B-specific CD4+ T cell responses.

Jeffrey R Maslanka, Qianxuan She, Kathleen S Krauss, Emily N Bitsko, Nile U Bayard, Jennifer A Londregan, Mohamad-Gabriel Alameh, Laurence C Eisenlohr, Michele A Kutzler, Joseph P Zackular and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Jeffrey R MaslankaDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-6982-5946
Qianxuan SheDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Kathleen S KraussDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Emily N BitskoDepartment of Medicine, Drexel University College of Medicine, Philadelphia, PA, United States.
Nile U BayardDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Jennifer A LondreganImmunology Graduate Group, University of Pennsylvania, Philadelphia, PA, United States.
Mohamad-Gabriel AlamehDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Laurence C EisenlohrDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, United States.
Michele A KutzlerDepartment of Medicine, Drexel University College of Medicine, Philadelphia, PA, United States.
Joseph P ZackularDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, United States.ORCID 0000-0002-3228-3055
Michael C AbtDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-7351-2061

Funding

National Institutes of Health/National Institute of Allergy and Infectious Diseases R01AI158830
6 · The paper itself

Abstract

The gastrointestinal pathogen Clostridioides difficile is a major burden for health systems due to high rates of recurrence. C. difficile pathogenesis is mediated by two virulence factors, toxin A (TcdA) and toxin B (TcdB). Antibodies specific for TcdA and TcdB are correlated with protection from symptomatic recurrence; however, the role for CD4+ T cells is poorly understood in part due to the lack of tools to study the toxin-specific CD4+ T cell response. Our group recently demonstrated the antibody and CD4+ T cell response to C. difficile toxins is impaired via the glucosyltransferase activity of the toxins; however, tools do not exist to study the protective capacity and the phenotype of toxin-specific CD4+ T cells. Therefore, we developed a major histocompatibility complex class II (MHC-II) tetramer to identify TcdB-specific CD4+ T cells via flow cytometry. Herein, we identified an immunodominant epitope (TcdB1961-1975) in the CROPs region of TcdB and optimized an MHC-II tetramer for use in tracking and phenotyping TcdB-specific CD4+ T cell responses following multiple different immunization strategies in mice. Utilizing the tetramer, TcdB-specific T follicular helper cells were detected following TcdB-CROPs messenger RNA lipid nanoparticle vaccination validating the advantage of the tetramer. Furthermore, using a modular messenger RNA vector expressing the TcdB1961 peptide covalently bound to the beta chain of MHC-II, we were able to generate a robust population of TcdB-specific CD4+ T cells. These data outline the generation of new tools for the C. difficile field and lay the groundwork for future studies of toxin-specific CD4+ T cell responses.

Indexed as

Bacterial ProteinsBacterial ToxinsCD4-Positive T-LymphocytesClostridioides difficileClostridium InfectionsHistocompatibility Antigens Class IIAnimalsEnterotoxinsEpitopes, T-LymphocyteImmunodominant EpitopesMiceMice, Inbred C57BLBacterial ProteinsBacterial ToxinsEnterotoxinsEpitopes, T-LymphocyteHistocompatibility Antigens Class IIImmunodominant EpitopestoxB protein, Clostridium difficileCD4+ T cell epitopesC. difficilemRNA-LNPtetramertoxin B

Identifiers

PMID42601060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.